Loading organizations...
Smart Medical Systems has raised $8.0M across 1 funding round.
Smart Medical Systems has raised $8.0M in total across 1 funding round.
Smart Medical Systems has raised $8.0M in total across 1 funding round.
Smart Medical Systems's investors include aMoon Fund.
Smart Medical Systems is an Israeli technology company specializing in the development and manufacturing of advanced medical devices for gastroenterology and gastrointestinal endoscopy. Their flagship product, the G-EYE® Colonoscope, enhances colonoscopy procedures by improving visibility and scope stability, addressing challenges such as haustral folds that can obscure the field of view. The company primarily serves hospitals and clinics aiming to improve patient outcomes and elevate standards of care in gastrointestinal diagnostics and treatment. Their product portfolio also includes the NAVIAid AB and SPARK2C Inflation System, supporting endoscopic procedures with innovative tools. Smart Medical Systems has demonstrated growth momentum through FDA clearances and expanding clinical adoption, particularly in the US and Europe[1][3].
Founded in Israel, Smart Medical Systems emerged from a vision to improve gastrointestinal endoscopy through innovative technology. While specific founders' details are not widely publicized, the company’s leadership, including CEO Gadi Terliuc, has driven the evolution of their core product, the G-EYE® Colonoscope. The idea originated from the need to overcome limitations in traditional colonoscopy, such as incomplete visualization and scope instability, which can lead to missed lesions. Early pivotal moments include obtaining FDA 510(k) clearance for the G-EYE® Colonoscope and initiating clinical and commercial efforts in the US market, marking significant validation and expansion milestones[1][3].
Smart Medical Systems rides the growing trend of medical device innovation focused on minimally invasive diagnostics and enhanced visualization technologies. The timing is critical as healthcare systems worldwide emphasize early detection of colorectal diseases, including cancer, to improve survival rates and reduce costs. Market forces such as increasing colorectal cancer screening programs, rising demand for advanced endoscopic tools, and regulatory encouragement for innovative medical devices work in the company’s favor. By improving the standard of care in gastrointestinal endoscopy, Smart Medical Systems influences the broader ecosystem by setting new benchmarks for procedural quality and patient safety[1][3].
Looking ahead, Smart Medical Systems is poised to expand its footprint in the US and global markets by leveraging ongoing clinical validation and regulatory approvals. Trends shaping their journey include the integration of AI and digital health tools in endoscopy, which could complement their visualization technology. Their influence may evolve from a niche innovator to a standard-bearer in gastrointestinal diagnostics, potentially broadening their product line to cover other endoscopic applications. Continued focus on clinical outcomes and healthcare provider partnerships will be key to sustaining growth and impact in the evolving medical device landscape[1][3].
Smart Medical Systems has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series B in February 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2018 | $8.0M Series B | aMoon Fund |